A role for low-density lipoprotein-related receptor 5 (LRP5) in human bone was first established by the identification of genetic alterations that led to dramatic changes in bone mass. Shortly thereafter, mutations that altered the function of the sclerostin (SOST) gene were also associated with altered human bone mass. Subsequent studies of LRP5 and sclerostin have provided important insights into the mechanisms by which these proteins regulate skeletal homeostasis. LRP-5 Protein, Human, Recombinant (mFc) is expressed in HEK293 mammalian cells with C-mFc tag. The predicted molecular weight is 96 kDa and the accession number is O75197-1.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
100 μg | 5 days | $ 487.00 | |
500 μg | 5 days | $ 1,950.00 | |
1 mg | 5 days | $ 3,250.00 |
Description | A role for low-density lipoprotein-related receptor 5 (LRP5) in human bone was first established by the identification of genetic alterations that led to dramatic changes in bone mass. Shortly thereafter, mutations that altered the function of the sclerostin (SOST) gene were also associated with altered human bone mass. Subsequent studies of LRP5 and sclerostin have provided important insights into the mechanisms by which these proteins regulate skeletal homeostasis. LRP-5 Protein, Human, Recombinant (mFc) is expressed in HEK293 mammalian cells with C-mFc tag. The predicted molecular weight is 96 kDa and the accession number is O75197-1. |
Species | Human |
Expression System | HEK293 Cells |
Tag | C-mFc |
Accession Number | O75197-1 |
Synonyms | LRP7, EVR1, LR3VBCH2, HBM, LRP5, EVR4, VBCH2, OPS, BMND1OPTA1, LR3, OPPG, LRP-7, OPTA1, LRP-5, BMND1 |
Construction | Glu644-Gln1263 |
Protein Purity | > 95% as determined by Tris-Bis PAGE |
Molecular Weight | 96 kDa (predicted). Due to glycosylation, the protein migrates to 100-115 kDa based on Tris-Bis PAGE result. |
Endotoxin | < 1 EU/μg by the LAL method. |
Formulation | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization. |
Reconstitution | Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. |
Stability & Storage |
It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at-80℃. For reconstituted proteinsolutions, the solution can be stored at -20°c to -80'c for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
Shipping |
In general, Lyophilized powders are shipping with blue ice. |
Research Background | A role for low-density lipoprotein-related receptor 5 (LRP5) in human bone was first established by the identification of genetic alterations that led to dramatic changes in bone mass. Shortly thereafter, mutations that altered the function of the sclerostin (SOST) gene were also associated with altered human bone mass. Subsequent studies of LRP5 and sclerostin have provided important insights into the mechanisms by which these proteins regulate skeletal homeostasis. |
bottom
Please read the User Guide of Recombinant Proteins for more specific information.
LRP-5 Protein, Human, Recombinant (mFc) LRP7 BMND 1 EVR-4 EVR1 LR3VBCH2 HBM BMND-1 LRP5 VBCH-2 EVR4 OPTA 1 VBCH2 OPS EVR 1 OPTA-1 LR 3 BMND1OPTA1 LR3 OPPG LRP-7 OPTA1 EVR 4 LRP 7 VBCH 2 LRP 5 LR-3 LRP-5 EVR-1 BMND1 recombinant recombinant-proteins proteins protein